Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 11/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.60 |
| ▸ | RPS6KA1 | Q15418 | 4/20 | 0.60 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.60 |
| ▸ | GRK2 | P25098 | 1/20 | 0.43 |
| ▸ | GRK5 | P34947 | 1/20 | 0.43 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.41 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867552 | 0.86 | ROCK1 (0.70) | ROCK1ROCK2RPS6KA1RPS6KB1GRK2 | |
| SCHEMBL3885174 | 0.84 | ROCK1 (0.68) | ROCK1ROCK2RPS6KA1RPS6KB1GRK2 | |
| SCHEMBL4025245 | 0.83 | ROCK1 (0.66) | ROCK1ROCK2RPS6KA1RPS6KB1GRK2 | |
| SCHEMBL3893789 | 0.82 | ROCK1 (0.73) | ROCK1ROCK2RPS6KA1RPS6KB1GRK2 | |
| SCHEMBL3891191 | 0.79 | GPBAR1 (0.55) | GPBAR1PAX8 | |
| SCHEMBL3895665 | 0.79 | GPBAR1 (0.51) | GPBAR1PAX8 | |
| SCHEMBL2801740 | 0.76 | ROCK1 (1.00) | ROCK1ROCK2RPS6KA1RPS6KB1GRK2 | |
| SCHEMBL29366060 | 0.76 | ROCK1 (1.00) | ROCK1ROCK2RPS6KA1RPS6KB1GRK2 | |
| SCHEMBL3884931 | 0.75 | ROCK1 (0.60) | ROCK1ROCK2RPS6KA1RPS6KB1CYP3A4 | |
| SCHEMBL3884743 | 0.73 | ROCK1 (0.59) | ROCK1ROCK2RPS6KA1RPS6KB1GRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | claimed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | claimed |
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1718638-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1718638-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082890-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058384-A1 | Novel Compounds | ARHGDIB, TNK2, ROCK2 | ROCK1 6/4885ROCK2 3/4885RPS6KA1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.